USE OF EXTERNAL CONTROL DATA TO ADJUST FOR TREATMENT SWITCHING IN COST-EFFECTIVENESS ANALYSES: LISOCABTAGENE MARALEUCEL (LISO-CEL) VERSUS STANDARD OF CARE (SOC) IN SECOND-LINE RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA

被引：0
|
作者：
Chandler, C. [1 ]
Liu, F. F. [2 ]
Klijn, S. [2 ]
Elsada, A. [3 ]
Proskorovsky, I [4 ]
机构：
[1] Evidera PPD, Waltham, MA USA
[2] Bristol Myers Squibb, Princeton, NJ USA
[3] Bristol Myers Squibb, Denham, Bucks, England
[4] Evidera PPD, Bethesda, MD USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
MSR78
引用
收藏
页码：S407 / S408
页数：2
相关论文
共 50 条
  • [1] Cost-Effectiveness of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Treatment of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    Parker, Christopher
    Liu, Fei Fei
    Deger, Kristen
    Franco-Villalobos, Conrado
    Proskorovsky, Irina
    Keating, Scott J.
    Sorensen, Sonja
    Dorman, Emily
    BLOOD, 2021, 138
  • [2] Subgroup analyses of primary refractory vs early relapsed Large B-cell Lymphoma (LBCL) from the TRANSFORM study of lisocabtagene maraleucel (liso-cel) vs Standard of Care (SOC) as second-line (2L) therapy
    Glass, B.
    Nastoupil, L.
    Kamdar, M.
    Chavez, J. C.
    Ghesquieres, H.
    Ghosh, M.
    Holmes, H.
    Lopez-Guillermo, A.
    Martinez-Lopez, J.
    Novak, U.
    Ribrag, V
    Roddie, C.
    Waller, E. K.
    Feldman, T.
    Rosenthal, A. C.
    Sauter, C.
    von Bonin, M.
    Karmali, R.
    Montheard, S.
    Previtali, A.
    Abramson, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 210 - 211
  • [3] COST-EFFECTIVENESS ANALYSIS OF SECOND-LINE TREATMENT WITH LISOCABTAGENE MARALEUCEL VERSUS STANDARD OF CARE FOR PATIENTS WITH LARGE B-CELL LYMPHOMA IN THE NETHERLANDS
    Buisman, L.
    Elsada, A.
    Klijn, S.
    Chavan, A.
    Pham, H. A.
    Sillem, E.
    Deger, K.
    van Beekhuizen, S.
    Pompen, M.
    Foo, J.
    VALUE IN HEALTH, 2024, 27 (12) : S73 - S73
  • [4] COST EFFECTIVENESS OF THE CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL TREATMENT LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE (2L) TREATMENT OF RELAPSED OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL) IN SWITZERLAND
    Deger, K.
    Oniangue-Ndza, C.
    Elsada, A.
    Litkiewicz, M.
    Villalobos, Franco C.
    Sorensen, S.
    VALUE IN HEALTH, 2023, 26 (12) : S152 - S153
  • [5] Subgroup analyses of primary refractory (refr) vs early relapsed (rel) large B-cell lymphoma (LBCL) from the TRANSFORM study of lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) as second-line (2L) therapy.
    Nastoupil, Loretta J.
    Kamdar, Manali K.
    Chavez, Julio C.
    Ghesquieres, Herve
    Ghosh, Monalisa
    Holmes, Houston
    Guillermo, Armando Lopez
    Martinez-Lopez, Joaquin
    Novak, Urban
    Ribrag, Vincent
    Roddie, Claire
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Cost-Effectiveness of the Chimeric Antigen Receptor (CAR) T-Cell Treatments, Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel), as Second-Line (2L) Treatment of Large B-Cell Lymphoma (LBCL)
    Lunning, Matthew
    Deger, Kristen A.
    Liu, Fei Fei
    Elsada, Ahmed
    Klijn, Sven L.
    Litkiewicz, Michal
    Franco-Villalobos, Conrado
    Sorensen, Sonja V.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S517 - S517
  • [7] Lisocabtagene Maraleucel (Liso-cel) vs Standard of Care (SOC) with Salvage Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) as Second-Line Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 TRANSFORM Study
    Glass, B.
    Abramson, J. S.
    Solomon, S. R.
    Arnason, J. E.
    Johnston, P. B.
    Bachanova, V
    Ibrahimi, S.
    Mielke, S.
    Mutsaers, P.
    Hernandez-Ilizaliturri, F.
    Izutsu, K.
    Morschhauser, F.
    Lunning, M. A.
    Crotta, A.
    Montheard, S.
    Previtali, A.
    Kamdar, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 272 - 273
  • [8] Comparative efficacy of tisagenlecleucel (tisa-cel) and lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL).
    Schuster, Stephen J.
    Zhang, Jie
    Yang, Hongbo
    Agarwal, Abhijit
    Tang, Wenxi
    Martinez-Prieto, Marcela
    Bollu, Vamsi
    Ma, Qiufei
    Kuzan, David
    Maziarz, Richard T.
    Kersten, Marie Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 Transform Study
    Abramson, Jeremy S.
    Solomon, Scott R.
    Arnason, Jon E.
    Johnston, Patrick B.
    Glass, Bertram
    Bachanova, Veronika
    Ibrahimi, Sami
    Mielke, Stephan
    Mutsaers, Pim
    Hernandez-Ilizaliturri, Francisco
    Izutsu, Koji
    Morschhauser, Franck
    Lunning, Matthew A.
    Crotta, Alessandro
    Montheard, Sandrine
    Previtali, Alessandro
    Kamdar, Manali
    BLOOD, 2022, 140 : 1581 - 1583
  • [10] TRANSCEND: Lisocabtagene Maraleucel (liso-cel; JCAR017) Healthcare Resource Utilization in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
    Palomba, M. Lia
    Garcia, Jacob
    Wang, Lei
    Dehner, Christine
    Chung, Karen C.
    Maloney, David G.
    BLOOD, 2018, 132
12345